Prevents postmenopausal osteoporosis. ANDA 78948, held by Apotex Inc. Ibandronate Sodium.
As of Nov 16, 2026, ANDA 78948 (Ibandronate Sodium), held by Apotex Inc, was first approved by FDA on Mar 19, 2012, with 6 approved supplements and 0 published complete response letters.
Ibandronate sodium tablet is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis.. Limitations of Use The optimal duration of use has not been determined. For patients at low -risk for fracture, consider drug discontinuation after 3 to 5 years of use.. 1.1 Treatment and Prevention of Postmenopausal Osteoporosis Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate sodium increases bone mineral density (BMD) and reduces the incidence of vertebral fractures. 1.2 Important Limitations of Use Theoptimalduration of use has not been determined.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 19, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ibandronate SodiumEQ 150MG BASE · tablet;oral | Ibandronate Sodium | Rx |
| Feb 3, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 27, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 23, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 24, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 24, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 24, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 19, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters